Different serum enzyme levels are required to rescue the various systemic features of the mucopolysaccharidoses

Gabriella Cotugno, Alessandra Tessitore, Anita Capalbo, Patrizia Annunziata, Caterina Strisciuglio, Armida Faella, Michela Aurilio, Maurizio Di Tommaso, Fabio Russo, Antonio Mancini, Elvira De Leonibus, Luigi Aloj, Alberto Auricchio

Research output: Contribution to journalArticle

Abstract

Mucopolysaccharidoses (MPSs) are lysosomal storage disorders characterized by progressive accumulation of glycosaminoglycans (GAGs) in various tissues. Enzyme replacement therapy (ERT) for several MPSs is available to date. However, the efficacy of ERT is limited, in particular in compartments such as bone, cartilage, the brain, and the eyes. We selected a rodent model of an MPS, with no central nervous system storage, to study the impact, on systemic features of the disease, of various stable levels of exogenous enzymes produced by adeno-associated viral vector (AAV)-mediated liver gene transfer. Low levels (6% of normal) of circulating enzyme were enough to reduce storage and inflammation in the visceral organs and to ameliorate skull abnormalities; intermediate levels (11% of normal) were required to reduce urinary GAG excretion; and high levels (≥50% of normal) rescued abnormalities of the long bones and motor activity. These data will be instrumental to design appropriate clinical protocols based on either enzyme or gene replacement therapy for MPS and to predict their impact on the pathological features of MPS.

Original languageEnglish
Pages (from-to)555-569
Number of pages15
JournalHuman Gene Therapy
Volume21
Issue number5
DOIs
Publication statusPublished - May 1 2010

Fingerprint

Mucopolysaccharidoses
Enzyme Replacement Therapy
Enzymes
Serum
Glycosaminoglycans
Bone and Bones
Clinical Protocols
Skull
Genetic Therapy
Cartilage
Rodentia
Motor Activity
Central Nervous System
Inflammation
Liver
Brain
Genes

ASJC Scopus subject areas

  • Molecular Medicine
  • Molecular Biology
  • Genetics

Cite this

Cotugno, G., Tessitore, A., Capalbo, A., Annunziata, P., Strisciuglio, C., Faella, A., ... Auricchio, A. (2010). Different serum enzyme levels are required to rescue the various systemic features of the mucopolysaccharidoses. Human Gene Therapy, 21(5), 555-569. https://doi.org/10.1089/hum.2009.189

Different serum enzyme levels are required to rescue the various systemic features of the mucopolysaccharidoses. / Cotugno, Gabriella; Tessitore, Alessandra; Capalbo, Anita; Annunziata, Patrizia; Strisciuglio, Caterina; Faella, Armida; Aurilio, Michela; Di Tommaso, Maurizio; Russo, Fabio; Mancini, Antonio; De Leonibus, Elvira; Aloj, Luigi; Auricchio, Alberto.

In: Human Gene Therapy, Vol. 21, No. 5, 01.05.2010, p. 555-569.

Research output: Contribution to journalArticle

Cotugno, G, Tessitore, A, Capalbo, A, Annunziata, P, Strisciuglio, C, Faella, A, Aurilio, M, Di Tommaso, M, Russo, F, Mancini, A, De Leonibus, E, Aloj, L & Auricchio, A 2010, 'Different serum enzyme levels are required to rescue the various systemic features of the mucopolysaccharidoses', Human Gene Therapy, vol. 21, no. 5, pp. 555-569. https://doi.org/10.1089/hum.2009.189
Cotugno G, Tessitore A, Capalbo A, Annunziata P, Strisciuglio C, Faella A et al. Different serum enzyme levels are required to rescue the various systemic features of the mucopolysaccharidoses. Human Gene Therapy. 2010 May 1;21(5):555-569. https://doi.org/10.1089/hum.2009.189
Cotugno, Gabriella ; Tessitore, Alessandra ; Capalbo, Anita ; Annunziata, Patrizia ; Strisciuglio, Caterina ; Faella, Armida ; Aurilio, Michela ; Di Tommaso, Maurizio ; Russo, Fabio ; Mancini, Antonio ; De Leonibus, Elvira ; Aloj, Luigi ; Auricchio, Alberto. / Different serum enzyme levels are required to rescue the various systemic features of the mucopolysaccharidoses. In: Human Gene Therapy. 2010 ; Vol. 21, No. 5. pp. 555-569.
@article{51e5a440d40547da8b809b80587a19da,
title = "Different serum enzyme levels are required to rescue the various systemic features of the mucopolysaccharidoses",
abstract = "Mucopolysaccharidoses (MPSs) are lysosomal storage disorders characterized by progressive accumulation of glycosaminoglycans (GAGs) in various tissues. Enzyme replacement therapy (ERT) for several MPSs is available to date. However, the efficacy of ERT is limited, in particular in compartments such as bone, cartilage, the brain, and the eyes. We selected a rodent model of an MPS, with no central nervous system storage, to study the impact, on systemic features of the disease, of various stable levels of exogenous enzymes produced by adeno-associated viral vector (AAV)-mediated liver gene transfer. Low levels (6{\%} of normal) of circulating enzyme were enough to reduce storage and inflammation in the visceral organs and to ameliorate skull abnormalities; intermediate levels (11{\%} of normal) were required to reduce urinary GAG excretion; and high levels (≥50{\%} of normal) rescued abnormalities of the long bones and motor activity. These data will be instrumental to design appropriate clinical protocols based on either enzyme or gene replacement therapy for MPS and to predict their impact on the pathological features of MPS.",
author = "Gabriella Cotugno and Alessandra Tessitore and Anita Capalbo and Patrizia Annunziata and Caterina Strisciuglio and Armida Faella and Michela Aurilio and {Di Tommaso}, Maurizio and Fabio Russo and Antonio Mancini and {De Leonibus}, Elvira and Luigi Aloj and Alberto Auricchio",
year = "2010",
month = "5",
day = "1",
doi = "10.1089/hum.2009.189",
language = "English",
volume = "21",
pages = "555--569",
journal = "Human Gene Therapy",
issn = "1043-0342",
publisher = "Mary Ann Liebert Inc.",
number = "5",

}

TY - JOUR

T1 - Different serum enzyme levels are required to rescue the various systemic features of the mucopolysaccharidoses

AU - Cotugno, Gabriella

AU - Tessitore, Alessandra

AU - Capalbo, Anita

AU - Annunziata, Patrizia

AU - Strisciuglio, Caterina

AU - Faella, Armida

AU - Aurilio, Michela

AU - Di Tommaso, Maurizio

AU - Russo, Fabio

AU - Mancini, Antonio

AU - De Leonibus, Elvira

AU - Aloj, Luigi

AU - Auricchio, Alberto

PY - 2010/5/1

Y1 - 2010/5/1

N2 - Mucopolysaccharidoses (MPSs) are lysosomal storage disorders characterized by progressive accumulation of glycosaminoglycans (GAGs) in various tissues. Enzyme replacement therapy (ERT) for several MPSs is available to date. However, the efficacy of ERT is limited, in particular in compartments such as bone, cartilage, the brain, and the eyes. We selected a rodent model of an MPS, with no central nervous system storage, to study the impact, on systemic features of the disease, of various stable levels of exogenous enzymes produced by adeno-associated viral vector (AAV)-mediated liver gene transfer. Low levels (6% of normal) of circulating enzyme were enough to reduce storage and inflammation in the visceral organs and to ameliorate skull abnormalities; intermediate levels (11% of normal) were required to reduce urinary GAG excretion; and high levels (≥50% of normal) rescued abnormalities of the long bones and motor activity. These data will be instrumental to design appropriate clinical protocols based on either enzyme or gene replacement therapy for MPS and to predict their impact on the pathological features of MPS.

AB - Mucopolysaccharidoses (MPSs) are lysosomal storage disorders characterized by progressive accumulation of glycosaminoglycans (GAGs) in various tissues. Enzyme replacement therapy (ERT) for several MPSs is available to date. However, the efficacy of ERT is limited, in particular in compartments such as bone, cartilage, the brain, and the eyes. We selected a rodent model of an MPS, with no central nervous system storage, to study the impact, on systemic features of the disease, of various stable levels of exogenous enzymes produced by adeno-associated viral vector (AAV)-mediated liver gene transfer. Low levels (6% of normal) of circulating enzyme were enough to reduce storage and inflammation in the visceral organs and to ameliorate skull abnormalities; intermediate levels (11% of normal) were required to reduce urinary GAG excretion; and high levels (≥50% of normal) rescued abnormalities of the long bones and motor activity. These data will be instrumental to design appropriate clinical protocols based on either enzyme or gene replacement therapy for MPS and to predict their impact on the pathological features of MPS.

UR - http://www.scopus.com/inward/record.url?scp=77951971556&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77951971556&partnerID=8YFLogxK

U2 - 10.1089/hum.2009.189

DO - 10.1089/hum.2009.189

M3 - Article

C2 - 20021231

AN - SCOPUS:77951971556

VL - 21

SP - 555

EP - 569

JO - Human Gene Therapy

JF - Human Gene Therapy

SN - 1043-0342

IS - 5

ER -